| 1 |
31655296 | Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses. | 2020 Feb |
2 |
| 2 |
32608142 | A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. | 2020 Oct |
1 |
| 3 |
30226440 | c-Myc Is a Major Determinant for Antitumor Activity of Aurora A Kinase Inhibitor MLN8237 in Thyroid Cancer. | 2018 Dec |
1 |
| 4 |
24893165 | Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2. | 2014 |
1 |